Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 30Terminated 4Recruiting 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Small Cell Lung Carcinoma 9Ovarian Neoplasms 8Neuroblastoma 4Retinoblastoma 3Fallopian Tube Neoplasms 3Sarcoma, Ewing 2Lung Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Wilms Tumor 1Uterine Cervical Neoplasms 1Recurrence 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1Medulloblastoma 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Glioma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 49Carboplatin 44Magnetic Resonance Spectroscopy 40Specimen Handling 39Pemetrexed 34Cisplatin 25Blood Specimen Collection 25durvalumab 17Paclitaxel 16osimertinib 15Radiotherapy 15Radiosurgery 15Bevacizumab 15Gemcitabine 14atezolizumab 13Nivolumab 13Biopsy 13Drug Therapy 12Standard of Care 10Practice Guidelines as Topic 10Immunoglobulin G 10Docetaxel 10130-nm albumin-bound paclitaxel 10X-Rays 9Taxes 9Educational Status 9Disulfides 9tislelizumab 8Etoposide 8Cetuximab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Lung Neoplasms × Topotecan × Clear all
NCT07099898 2026-05-27

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)

GlaxoSmithKline

Phase 3 Recruiting
420 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05800587 2026-05-22

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2 Recruiting
280 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡